Curebase Releases New Diagnostic Offering
Curebase announced the release of an integrated, plug-and-play software offering that allows sponsors of diagnostic studies to accelerate enrollment and launch their trials more quickly, as the sole execution partner.
Read more about the new offering here.
Related Content
Diagnostic Tool That Identifies Patients Suitable for Keytruda Treatment Gets Latest FDA Approval
November 14th 2023Articles
PD-L1 IHC 22C3 pharmD approved to help identify patients who may be eligible to receive treatment with pembrolizumab (Keytruda) to treat gastric or gastroesophageal junction adenocarcinoma.
